These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1250 related items for PubMed ID: 12486414

  • 1. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM.
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [Abstract] [Full Text] [Related]

  • 2. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 3. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    J Am Coll Cardiol; 2004 Aug 04; 44(3):720-32. PubMed ID: 15358046
    [Abstract] [Full Text] [Related]

  • 4. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, Coordinating Committee of the National Cholesterol Education Program.
    Arterioscler Thromb Vasc Biol; 2004 Aug 04; 24(8):e149-61. PubMed ID: 15297292
    [Abstract] [Full Text] [Related]

  • 5. Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.
    Bersot TP, Pépin GM, Mahley RW.
    Am Heart J; 2003 Dec 04; 146(6):1052-9. PubMed ID: 14660998
    [Abstract] [Full Text] [Related]

  • 6. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target.
    Maki KC, Galant R, Davidson MH.
    Am J Cardiol; 2005 Nov 07; 96(9A):59K-64K; discussion 34K-35K. PubMed ID: 16291016
    [Abstract] [Full Text] [Related]

  • 7. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 07; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 8. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S.
    Am J Cardiol; 2009 Jan 01; 103(1):41-5. PubMed ID: 19101227
    [Abstract] [Full Text] [Related]

  • 9. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
    Miller M, Ginsberg HN, Schaefer EJ.
    Am J Cardiol; 2008 Apr 01; 101(7):1003-8. PubMed ID: 18359322
    [Abstract] [Full Text] [Related]

  • 10. The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
    Assmann G, Schulte H, Funke H, von Eckardstein A.
    Eur Heart J; 1998 Oct 01; 19 Suppl M():M8-14. PubMed ID: 9821011
    [Abstract] [Full Text] [Related]

  • 11. Rising to the challenge of the new NCEP ATP III guidelines: exceeding current therapeutic limitations.
    Brewer HB.
    Am J Manag Care; 2002 Feb 01; 8(2 Suppl):S23-8; discussion S45-7. PubMed ID: 11855698
    [Abstract] [Full Text] [Related]

  • 12. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Daskalopoulou SS, Kakafika AI, Pehlivanidis AN, Bouloukos VI, Langer A, GREACE Study Collaborative Group.
    Curr Med Res Opin; 2004 Sep 01; 20(9):1385-92. PubMed ID: 15383187
    [Abstract] [Full Text] [Related]

  • 13. Role of lipid and lipoprotein profiles in risk assessment and therapy.
    Ballantyne CM, Hoogeveen RC.
    Am Heart J; 2003 Aug 01; 146(2):227-33. PubMed ID: 12891189
    [Abstract] [Full Text] [Related]

  • 14. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A, LIPID Study Investigators.
    Eur Heart J; 2004 May 01; 25(9):771-7. PubMed ID: 15120888
    [Abstract] [Full Text] [Related]

  • 15. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM.
    Circulation; 2003 Dec 02; 108(22):2751-6. PubMed ID: 14638544
    [Abstract] [Full Text] [Related]

  • 16. Niacin-based therapy for dyslipidemia: past evidence and future advances.
    Ito MK.
    Am J Manag Care; 2002 Sep 02; 8(12 Suppl):S315-22. PubMed ID: 12240703
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES.
    J Am Coll Cardiol; 2005 Jan 18; 45(2):185-97. PubMed ID: 15653014
    [Abstract] [Full Text] [Related]

  • 18. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ, Chen ML, Wang S, Dong J, Zeng P, Hou LW.
    Chin Med J (Engl); 2004 Feb 18; 117(2):163-7. PubMed ID: 14975195
    [Abstract] [Full Text] [Related]

  • 19. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul 18; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 20. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events.
    Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM.
    Am Heart J; 2006 Mar 18; 151(3):755.e1-755.e6. PubMed ID: 16504648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.